Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients

Belenchón, I. Rivero; Osmán-García, I.; Congregado-Ruíz, C.B.; Cabrera-Roldán, Patricia; Jiménez-Torres, M.J.; Baeza-Trujillo, Montserrat; Lendínez-Cano, G.; Conde-Sánchez, J.M.; Argüelles-Salido, E.; Ortiz-Gordilo, M.J.; Medina-López, R.A.

doi:10.1016/j.brachy.2018.06.001

Cited by 5 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSA screening for renal transplant patients prior to prostate cancer diagnosis was mentioned in only seven studies with the most common protocol being yearly PSA and digital rectal examination from the age of 50. 12,16,26,63,64,67,68 Overall, 410 (78%) patients underwent surgery, 93 (18%) patients underwent radiation therapy or brachytherapy, one patient underwent focal therapy (HIFU) and 21 patients were placed on active surveillance. The mean age was 61 years old, the mean PSA level at diagnosis was 9.6 ng/mL and the mean follow-up time was 31 months.…”

Section: Study Characteristics and Results Of Individual Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The role of localised prostate cancer treatment in renal transplant patients: A systematic review

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo systematically review and critically appraise all treatment options for localised prostate cancer in renal transplant candidates and recipients.MethodA systematic review was conducted adhering to PRISMA guidelines. Searches were performed in the Cochrane Library, Embase, Medline, the Transplant Library and Trip database for studies published up to September 2022. Risk of bias was assessed with the Cochrane Risk of Bias in Non‐Randomised Studies of Interventions for non‐randomised studies tool.ResultsA total of 60 studies were identified describing 525 patients. The majority of studies were either retrospective non‐randomised comparative or case series/reports of poor quality. The vast majority of studies were focussed on prostate cancer after renal transplantation. Overall, 410 (78%) patients underwent surgery, 93 (18%) patients underwent radiation therapy or brachytherapy, one patient underwent focal therapy (high‐intensity frequency ultrasound) and 21 patients were placed on active surveillance. The mean age was 61 years old, the mean PSA level at diagnosis was 9.6 ng/mL and the mean follow‐up time was 31 months. The majority of patients had low‐risk disease with 261 patients having Gleason 6 prostate cancer (50%), followed by 220 Gleason 7 patients (42%). All prostate cancer mortality cases were in high‐risk prostate cancer (≥Gleason 8). The cancer‐specific survival results were similar between surgery and radiotherapy at 1 and 3 years.ConclusionLocalised prostate cancer treatment in renal transplant patients should be risk stratified. Surgery and radiation treatment for localised prostate cancer in renal transplant patients appear equally efficacious. Given the limitations of this study, future research should concentrate on developing a multicentre RCT with long‐term registry follow‐up.

show abstract

Section: Study Characteristics and Results Of Individual Studiesmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The role of localised prostate cancer treatment in renal transplant patients: A systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We also experienced no graft loss or changes in renal function after PCa treatment, and this is supported by other studies. Although immuno-suppression has been implicated in malignant cell growth, it is uncertain if prostate cancer runs a more aggressive course in renal transplant recipients [12], but androgen deprivation therapy also has a crucial role in the radio-therapeutic management of intermediate-and high-risk PCa [13]. To our knowledge, this is the first study that focuses on a series of kidney transplant patients with prostate cancer treated with a combination of radiotherapy, either EBRT or BT, and androgen deprivation therapy (delivered over 12 months), which resulted in long-term prostate cancer clinical remission.…”

Section: Resultsmentioning

confidence: 99%

“…A recent review of treatment approaches in renal transplant recipients with diagnosed PCa reports that the most frequent treatment is surgery (n=186), with overall survival rates of 96.8% [7]. Further, only 20 renal transplant recipients with PCa undergoing brachytherapy treatment have been reported in the literature (Table 2); and all as solo therapy [8][9][10][11][12]. Herein, we report our experience with four patients diagnosed with PCa after renal transplantation and undergoing radiotherapy treatment (three had BT and one had external beam radiotherapy).…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy of prostate cancer in renal transplant recipients: single-center experience

Gojdic

Žilinská

Krajcovicova

et al. 2019

neo

View full text Add to dashboard Cite

This study analyzed the long-term outcomes of localized prostate cancer in renal transplant recipients after radiotherapy treatment-mainly brachytherapy. We retrospectively analyzed clinical data of renal transplant recipients between 2003 and 2016 at a single tertiary center, and identified four patients with high serum PSA level during regular follow-up, 1-108 months after primary renal transplantation. The mean age of patients with detected high serum PSA level with 9.25µg/l median was 59.05 years. All four patients had functioning grafts. To prove prostate cancer, they underwent trans-rectal prostate biopsy, with no complications. Histological evaluation identified prostate adenocarcinoma (Gleason 6-7, stage T1-2cN0M0) in three patients. The biopsy in the fourth patient was negative and he therefore had trans-urethral prostate resection. Histological evaluation of resected prostate tissue revealed prostate adenocarcinoma (Gleason 7, 4+3). All patients began treatment with androgen deprivation therapy. Three patients were indicated for permanent prostate brachytherapy (BT) with iodine-125 (125 I) seeds and the trans-urethral resection patient was referred for external beam radiotherapy (EBRT). After a mean follow-up of 49 months (range, 30-73), all patients, irrespective of type of radiotherapy, were in complete clinical and biochemical remission, with undetectable PSA levels. The kidney grafts remained functional, with a mean creatinine level of 99 µmol/l (range 64-123) and a glomerular filtration rate of 1.17 ml/s/1.73 m 2 (range, 0.89-1.59). Radiation-induced late adverse effects were reported in two BT patients; one had clinically significant urine incontinency and the other suffered urethral stricture. Localized prostate tumor was identified in all reported patients, and all received radiotherapy plus androgen deprivation. All patients were disease-free at the time of the last follow-up. Therefore, combined BT and twelve months androgen deprivation appears both safe and effective for patients with prostate cancer after kidney transplantation.

show abstract

Recommandations françaises du Comité de transplantation de l’Association française d’urologie (CTAFU) : cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation

Culty

Goujon

Defortescu

et al. 2021

Progrès en Urologie

View full text Add to dashboard Cite

Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients

Cited by 5 publications

References 39 publications

The role of localised prostate cancer treatment in renal transplant patients: A systematic review

The role of localised prostate cancer treatment in renal transplant patients: A systematic review

Radiotherapy of prostate cancer in renal transplant recipients: single-center experience

Recommandations françaises du Comité de transplantation de l’Association française d’urologie (CTAFU) : cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation

Contact Info

Product

Resources

About